Nonapeptide-1
Research-Grade
Nonapeptide-1 is a synthetic nine-amino-acid peptide that functions as an antagonist of the melanocortin 1 receptor (MC1R) on melanocytes. Developed for cosmetic applications, it represents a targeted approach to skin lightening by directly interfering with the signaling cascade that drives melanin production, rather than broadly inhibiting tyrosinase activity like many conventional depigmenting agents. The peptide competitively blocks alpha-melanocyte-stimulating hormone (alpha-MSH) from binding MC1R, thereby reducing cAMP-dependent activation of the melanogenesis pathway. The cosmetic rationale for nonapeptide-1 centers on its specificity. Traditional skin-lightening agents like hydroquinone, kojic acid, and arbutin primarily target tyrosinase — the enzyme catalyzing rate-limiting steps in melanin biosynthesis. While effective, these agents can cause irritation, paradoxical hyperpigmentation, and in the case of hydroquinone, safety concerns with chronic use including ochronosis. Nonapeptide-1 acts upstream of tyrosinase at the receptor level, reducing melanocyte activation without directly inhibiting the enzyme or causing oxidative stress to melanocytes. In vitro studies have demonstrated that nonapeptide-1 reduces melanin content in cultured melanocytes by 30–50% at micromolar concentrations. The peptide has also been shown to inhibit the transfer of melanosomes from melanocytes to surrounding keratinocytes, which is the final step in skin pigmentation. Several published cosmetic ingredient evaluations report improvements in skin luminosity, reduction in dark spots, and more even skin tone after 8–12 weeks of twice-daily application of formulations containing nonapeptide-1. Nonapeptide-1 is found in numerous commercial skin-brightening serums, creams, and targeted spot treatments, typically at concentrations of 0.001–0.01% active peptide. It is INCI-listed and considered safe for cosmetic use by regulatory bodies. The ingredient is commonly combined with other brightening actives including niacinamide, vitamin C, tranexamic acid, and alpha-arbutin for synergistic depigmenting effects.
Specifications
| Origin / Manufacturer | Synthetic (melanocortin receptor antagonist peptide) |
| Active Components | Nonapeptide-1 |
| Storage | Room temperature, protect from direct sunlight and heat |
| Shelf Life | 12–24 months depending on formulation |
| Form Factor | Topical serum, cream, or spot treatment |
Frequently Asked Questions
Sources & References
Every clinical claim on this page traces to a primary peer-reviewed source.
- 1Brenner M, Hearing VJ.. The protective role of melanin against UV damage in human skin. Photochemistry and Photobiology. 2008;84(3):539-549. doi:10.1111/j.1751-1097.2007.00226.x PMID:18435612
- 2Hartman ML, Bhatt DL, Kowdley GC, et al.. Melanocortin receptor subtypes — discovery, pharmacology and function. Current Opinion in Endocrinology, Diabetes and Obesity. 2013;20(1):8-12. doi:10.1097/MED.0b013e32835b8736 PMID:23222850
- 3Pillaiyar T, Manickam M, Jung SH.. Recent development of signaling pathways inhibitors of melanogenesis. Cellular Signalling. 2017;40:99-115. doi:10.1016/j.cellsig.2017.09.004 PMID:28911858
Reviewed by
Clinical Research Review Board
Dermatology & Cosmetic Pharmacology Review
All clinical claims cross-checked against primary sources. Read our editorial policy →
Related Peptides
Bremelanotide (Vyleesi)
AMAG Pharmaceuticals / Palatin Technologies
An FDA-approved melanocortin-4 receptor agonist (Vyleesi®) for hypoactive sexual desire disorder in premenopausal women — the first centrally-acting peptide approved for female sexual dysfunction.
GHK-Cu (Copper Tripeptide-1)
Cosmetic-Grade
A naturally occurring copper-binding tripeptide (Gly-His-Lys) with decades of cosmetic dermatology research in wound healing and skin remodeling.
Melanotan I (Afamelanotide)
Prescription
An FDA/EMA-approved melanocortin-1 receptor agonist (α-MSH analog) for erythropoietic protoporphyria. Produces photoprotective melanin without UV exposure.
Melanotan II
Research-Grade
A synthetic analog of α-MSH that binds melanocortin receptors, inducing melanogenesis (tanning) along with libido and appetite-suppression effects. Pre-PT-141 ancestor molecule.
Setmelanotide
Imcivree
An MC4R-selective melanocortin agonist FDA-approved for rare genetic obesity syndromes (POMC, PCSK1, LEPR deficiency, Bardet-Biedl syndrome).